AFAndreas Franke

Andreas Franke

*This is an algorithmically generated author record based on publicly available information.

Andreas Franke has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sequential Switching Shunt Regulation Using DC Transformers for Solar Array Power Processing in High Voltage Satellites

    by Carlos Orts, Ausiàs Garrigós, David Marroquí, Andreas Franke

    This paper proposes a solar array regulation technique for a high-voltage satellite power bus. The regulation method combines on-off control at low frequency, i.e. kHz range, of highly efficient isolated and unregulated dc-dc converters operating at high frequency, i.e. hundreds of kHz. Although this technique can adopt different implementations, this paper deals with a hysteretic voltage control loop at low frequency, also known (Sequential Switching Shunt Regulator - S3R), and unregulated, isolated, current-fed, zero-voltage and zero-current push-pull dc-dc converters. Design guidelines and experimental validation are provided.


  • Open Access

    Outcomes of cryoballoon or radiofrequency ablation in symptomatic paroxysmal or persistent atrial fibrillation

    by Ellen Hoffmann, Florian Straube, Karl Wegscheider, Malte Kuniss, Dietrich Andresen, Li-Qun Wu, Jürgen Tebbenjohanns, Georg Noelker, Roland Richard Tilz, Julian Kyoung Ryul Chun, et al.

    To evaluate the effectiveness and safety of cryoballoon ablation (CBA) compared with radiofrequency ablation (RFA) for symptomatic paroxysmal or drug-refractory persistent atrial fibrillation (AF). Prospective cluster cohort study in experienced CBA and RFA centres. Primary endpoint was ‘atrial arrhythmia recurrence’, secondary endpoints were as follows: procedural results, safety, and clinical course. A total of 4189 patients were included: CBA 2329 (55.6%) and RFA 1860 (44.4%). Cryoballoon ablation population was younger, with fewer comorbidities. Procedure time was longer in the RFA group (P = 0.01). Radiation exposure was 2487 (CBA) and 1792 cGycm2 (RFA) (P < 0.001). Follow-up duration was 441 (CBA) and 511 days (RFA) (P < 0.0001). Primary endpoint occurred in 30.7% (CBA) and 39.4% patients (RFA) [adjusted hazard ratio (adjHR) 0.85, 95% confidence interval (CI) 0.70–1.04; P = 0.12). In paroxysmal AF, CBA resulted in a lower risk of recurrence (adjHR 0.80, 95% CI 0.64–0.99; P = 0.047). In persistent AF, the primary outcome was not different between groups. Major adverse cardiovascular and cerebrovascular event rates were 1.0% (CBA) and 2.8% (RFA) (adjHR 0.53, 95% CI 0.26–1.10; P = 0.088). Re-ablations (adjHR 0.46, 95% CI 0.34–0.61; P < 0.0001) and adverse events during follow-up (adjHR 0.64, 95% CI 0.48–0.88; P = 0.005) were less common after CBA. Higher rehospitalization rates with RFA were caused by re-ablations. The primary endpoint did not differ between CBA and RFA. Cryoballoon ablation was completed rapidly; the radiation exposure was greater. Rehospitalization due to re-ablations and adverse events during follow-up were observed significantly less frequently after CBA than after RFA. Subgroup analysis suggested a lower risk of recurrence after CBA in paroxysmal AF. ClinicalTrials.gov (NCT01360008), https://clinicaltrials.gov/ct2/show/NCT01360008.